CSF2 and chronic myelomonocytic leukemia: Oncogenic signaling mutations in JAK2^V617F and NRAS both result in granulocyte-macrophage colony-stimulating factor (GM-CSF) hypersensitivity, a finding in >90% of CMML cases [16].